Unlike other synthesized matrices such as matrigel which originated from mice sarcoma, myogel is extracted from a human benign tumor tissue called leiomyoma.
Myogel was developed in Tuula Salo's lab at the University of Oulu.
The idea started in 2009 by culturing cancer cells on myoma discs.
[1] Later in 2015, these myoma tissues were processed following matrigel receipt, to extract a gel form called Myogel.
[2] Myogel was compared with matrigel and found to be superior in term of enhancing cancer cells proliferation, migration and invasion.